GE Announces Haliade-X, the World’s Most Powerful Offshore Wind Turbine
GE Renewable Energy (NYSE:GE) today unveiled its plan to develop the largest, most powerful offshore wind turbine: the Haliade-X. Featuring a 12 MW direct drive generator and an industry leading gross capacity factor of 63 percent, the Haliade-X will produce 45 percent more energy than any other offshore turbine available today 2 . GE will invest more than $400 million over the next three to five years in development and deployment of the Haliade-X.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180301005661/en/
Featuring a 12 MW direct drive generator and an industry leading gross capacity factor of 63 percent, the Haliade-X will produce 45 percent more energy than any other offshore turbine available today. (Photo: Business Wire)
John Flannery, Chairman and CEO of GE said, “We want to lead in the technologies that are driving the global energy transition. Offshore wind is one of those technologies and we will bring the full resources of GE to make the Haliade-X program successful for our customers.”
Towering 260 meters over the sea, more than five times the size of the iconic Arc de Triomphe in Paris, France, the Haliade-X 12 MW carries a 220-meter rotor. Designed and manufactured by LM Wind Power, the 107-meter-long blades will be the longest offshore blades to date and will be longer than the size of a soccer field. One Haliade-X 12 MW turbine will generate up to 67 GWh annually 2 , enough clean power for up to 5,000 households per turbine, and up to 300,000 U.S. households in a 750 MW windfarm configuration.
Jérôme Pécresse, President and CEO of GE Renewable Energy said, “The renewables industry took more than 20 years to install the first 17 GW of offshore wind. Today, the industry forecasts that it will install more than 90 GW over the next 12 years. This is being driven by lower cost of electricity from scale and technology. The Haliade-X shows GE’s commitment to the offshore wind segment and will set a new benchmark for cost of electricity, thus driving more offshore growth.”
The ability to produce more power from a single turbine means a smaller number of turbines in the total farm, which translates to less capital expenditure for the balance of plant and reduced risk in project execution as the installation cycle time is reduced. It also simplifies operation and maintenance of the wind farm. All of this reduces the investment and operation cost for developers, makes offshore wind projects more profitable, and ultimately lowers cost of electricity for consumers.
John Lavelle, CEO of Offshore Wind at GE Renewable Energy said “The Haliade-X 12 MW will help our customers in an increasingly competitive offshore environment, and through its size and digital functionality provide important value across manufacturing, installation and operation.”
GE’s Haliade-X platform is designed to offer greater efficiency in generating power from the wind that is available. With a 63 percent gross capacity factor1, the Haliade-X 12 MW is five to seven points above the current industry benchmark. Therefore, it will produce more energy per MW installed, which will significantly increase returns for customers.
To design and build the Haliade-X platform, GE Renewable Energy is relying on an unprecedented collaboration across the GE portfolio, leveraging the knowledge of GE’s Onshore wind team, with 50,000 turbines in the field; the blade expertise of LM Power Wind; the GE Power and GE Aviation engineers for peer reviews of component and systems design; the Global Research Center for control systems and component validation; and GE Digital for supporting digital modelling, analytics and app development, the program is a GE-wide effort.
GE Renewable Energy aims to supply its first nacelle for demonstration in 2019 and ship the first units in 2021.
1 “Capacity factor” compares how much energy was generated against the maximum that could have been produced at continuous full power operation during a specific period of time.
2 Based on wind conditions on a typical German North Sea site.
About GE Renewable Energy
GE Renewable Energy is a $10 billion start-up that brings together one of the broadest product and service portfolios of the renewable energy industry. Combining onshore and offshore wind, hydro and innovative technologies such as concentrated solar power and more recently turbine blades, GE Renewable Energy has installed more than 400+ gigawatt capacity globally to make the world work better and cleaner. With more than 22,000 employees present in more than 55 countries, GE Renewable Energy is backed by the resources of the world's first digital industrial company. Our goal is to demonstrate to the rest of the world that nobody should ever have to choose between affordable, reliable, and sustainable energy. Follow us @GErenewables and www.gerenewableenergy.com
GE Renewable Energy
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 18:28 | Pressemelding
Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (http://www.elektroniknet.de), a leading German electronics publication. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005646/en/ Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl
Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05 | Pressemelding
Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52 | Pressemelding
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50 | Pressemelding
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00 | Pressemelding
Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at www.aitheon.com/news) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005269/en/ Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on